Skip Navigation



NDT Advance Access published online on June 23, 2009
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfp306
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
24/10/3103    most recent
gfp306v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ferrario, F.
Right arrow Articles by Scorza, D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferrario, F.
Right arrow Articles by Scorza, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2009]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy—a randomized controlled study

Francesca Ferrario1, Maria Teresa Barone1, Giovanni Landoni2, Augusto Genderini1, Marco Heidemperger1, Matteo Trezzi1, Emanuela Piccaluga3, Paolo Danna3 and Daniele Scorza1

1 Nephrology and Dialysis Ospedale "L. Sacco" Milano, Italy 2 Department of Anesthesia and Intensive Care, Istituto Scientifico San Raffaele, Milano, Italy 3 Cardiology Department Ospedale "L. Sacco" Milano, Italy

Correspondence and offprint requests to: Giovanni Landoni; E-mail: landoni.giovanni{at}hsr.it



  Abstract

Introduction. Intravenous administration of saline and non-ionic isosmolar contrast media significantly reduces the incidence of contrast-induced nephropathy, one of the most common causes of acute renal failure. Results with oral N-acetylcysteine are conflicting. The aim of our study was to evaluate the prophylactic role of N-acetylcysteine in patients with stable chronic renal failure undergoing coronary and/or peripheral angiography and/or angioplasty.

Methods. We randomized 200 elective, consecutive patients (mean age 74.9 ± 7.3 years; 65% male, 25% diabetics) with basal creatinine clearance ≤55 ml/min to receive oral N-acetylcysteine (600 mg bid the day before and the day of the procedure plus saline i.v. 0.9% 1 ml/kg/h 12–24 h before and 24 h after the procedure, n = 99) or placebo and saline at the same time intervals, n = 101. The contrast medium was non-ionic isosmolar (Iodixanol, Visipaque Amersham Health). Contrast-induced nephropathy was defined as an increase in serum creatinine >0.5 mg/dl or >25% within 3 days after the procedure. Serum creatinine was measured at baseline, 24, 48 and 72 h after the procedure.

Results. Contrast-induced nephropathy was 8/99 (8.1%) in the N-acetylcysteine group versus 6/101 (5.9%) in the placebo group, P = 0.6. No difference was noted in high-risk subgroups such as diabetics (4/25 versus 2/25 P = 0.4) and those with serum creatinine clearance <42.3 ml/min (5/54 versus 4/48; P = 0.9).

Conclusion. In our experience, N-acetylcysteine did not prevent contrast-induced nephropathy in patients receiving isosmolar (iodixanol) contrast media and adequate hydration.

Keywords: acute renal failure; contrast nephropathy; isosmolar contrast media; N-acetylcysteine; renal replacement therapy

Received for publication: 13. 5.08
Accepted in revised form: 29. 5.09


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.